MPO and colitis: In the present study, we demonstrated that intrarectal administration of XLS suppresses DSS-induced colitis by decreasing the infiltration and migration of inflammatory cells into the colon, reducing colonic MPO activity, degrading the proinflammatory cytokines and chemokines, and promoting mucosal repair.